A pharmaceutical study on a hybrid system to improve oral delivery of hypoglycemic drugs: (Record no. 166026)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 07231namaa22004211i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240211192458.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 231217s2023 ua a|||f |m|| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - LOCAL HOLDINGS (OCLC) | |
| Holding library | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.19 |
| Edition number | 21 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.19 |
| Edition number | 21 |
| 097 ## - Thesis Degree | |
| Thesis Level | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Classification number | Cai01.08.10.Ph.D.2023.Re.P |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Reham Waheed Mahmoud Hammad, |
| Relator term | preparation. |
| 245 12 - TITLE STATEMENT | |
| Title | A pharmaceutical study on a hybrid system to improve oral delivery of hypoglycemic drugs: |
| Statement of responsibility, etc. | by RehamWaheed Mahmoud Hammad; under The Supervision of Prof. Nevine ShawkyAbd El-Malak, Prof. Dr. Randa Latif Aziz, Dr. Rania Abd El-Baset Sanad. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | دراسه صيدلانية علي نظام هجين لتحسين التوصيل الدوائي الفمي لأدوية السكر |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2023. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 167 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2023. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 151-167. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Linagliptin is a competitive, reversible inhibitor of DPP-4 (An enzyme that causes the inactivation of incretins hormones which stimulate the release of insulin from beta cells in the pancreas in a glucose-dependent manner while inhibiting the release of glucagon from pancreatic beta cells). These effects together reduce the breakdown of glycogen in the liver and increase insulin release in response to glucose.<br/>Empagliflozin is a selective sodium glucose co-transporter-2 (SGLT-2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes. SGLT2 co-transporters are responsible for the reabsorption of glucose from the glomerular filtrate in the kidney. Inhibition of SGLT2 decreases renal glucose reabsorption, promotes urinary glucose excretion and reduces plasma glucose concentration. Because SGLT2 inhibition occurs through an insulin-independent mechanism, the risk of hypoglycaemia is low.<br/>Linagliptin and empagliflozin are drugs combinations with complementary mechanisms of action to improve glycemic control in patients with type II diabetes, Licensed from Boehringer Ingelheim International GmbH, Ingelheim, Germany for oral administration. However, oral administration of linagliptin and empagliflozin may suffer from several drawbacks low oral bioavailability 30% for linagliptin (due to degradation by P-glycoprotein (P-gp) mediated efflux present in the intestine) and 78% for empagliflozin. Both drugs belong to Class-III in the BCS classification leading to low permeability. In addition, linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, and obeys concentration dependent protein binding.<br/>Buccal drug delivery can be used to improve oral bioavailability. Nanotechnology has encouraged the incorporation of nanoparticles in mucoadhesive film as a buccal drug delivery dosage form for the adjustment of drug properties and overcoming the mucus barrier.<br/>So, the aim of this study was the formulation of hybrid nanocarrier systems with a controlled drugs release and high permeation for these released drugs, namely multilayer nanosponge and cubosomes, for buccal delivery of linagliptin and empagliflozin to improve their clinical efficiency in the management of persistent hyperglycemic type II diabetes mellitus.<br/>The work in this thesis is divided into three chapters:<br/>Chapter I: Preparation and evaluation of multilayer nanosponge buccal film for co-administration of linagliptin and empagliflozin for better management of persistent hyperglycemic type II diabetes<br/>Chapter II: Preparation and evaluation of chitosan- PVP scaffold enriched with linagliptin and empagliflozin dual cubosomes for better management of persistent hyperglycemic type II diabetes<br/>Chapter III: In-vivo performance of the optimized linagliptin and empagliflozin formulations.<br/> |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | الهدف الرئيسي من هذا العمل هو تعزيز التوافر البيولوجي لعقاقير سكر الدم وهما الليناجليبتن و الإمباغليفلوزين من خلال تطبيق الأنظمة النانومترية الهجينة ، وتحديداً هما الإسفنج النانوي متعدد الطبقات والمكعبات النانومترية ، للتوصيل من خلال فيلم لاصق للتجويف الفمي وذلك لضمان استمرار إطلاق العقاقير وزيادة نفاذيتهما بغرض تحسين التوافر البيولوجي لكليهما . ليناجليبتن و إمباغليفلوزين عبارة عن مزيج من الأدوية لديهم آليات عمل تكميلية لتحسين التحكم في نسبة السكر في الدم لدى مرضى السكر من النوع الثاني. هذا المزيج مرخص للإعطاء عن طريق الفم. ومع ذلك ، قد يعاني تناول مزيج الليناجليبتن و الإمباغليفلوزين عن طريق الفم من عدة عيوب مثل انخفاض التوافر الحيوي عن طريق الفم بنسبة 30 ٪ لليناجليبتين (بسبب التحلل بواسطة البروتين السكري (P-glycoprotein) الموجود في الأمعاء) و 78 ٪ للإمباغليفلوزين. ينتمي كلا العقارين إلى الفئة الثالثة في تصنيف الصيدلة الحيوية مما يؤدي إلى نفاذية منخفضة. بالإضافة إلى ذلك ، يختلف ليناجليبتن عن مثبطات DPP-4 الأخرى من حيث أنه يحتوي على ملف تعريف حركي دوائي غير خطي ، ويتبع ارتباط البروتين المعتمد على التركيز. اشتمل العمل في هذه الرسالة على صياغة وتقييم أنظمة نانومترية هجينة وهي الإسفنج النانوي متعدد الطبقات والمكعبات النانومترية ، من أجل التوصيل الفمي لليناجليبتن و إمباغليفلوزين لتحسين كفاءتها السريرية في إدارة الداء السكري المستمرالمصاحب بارتفاع ضغط الدم من النوع الثاني من داء السكر. تم إجراء التقييمات في المختبر وداخل الجسم الحي للتركيبات المحسنة مقارنةً بمساحيق الأدوية والمنتج المسوق.<br/><br/> |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Additional physical form available note | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Language note | Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmaceutical |
| Source of heading or term | 1 |
| 653 #0 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Linagliptin |
| -- | empagliflozin |
| -- | cubosomes |
| -- | multilayer nanosponge |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nevine ShawkyAbd El-Malak |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Randa Latif Aziz |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rania Abd El-Baset Sanad |
| Relator term | thesis advisor. |
| 900 ## - EQUIVALENCE OR CROSS-REFERENCE-PERSONAL NAME [LOCAL, CANADA] | |
| Numeration | 01-01-2023 |
| Titles and other words associated with a name | Nevine ShawkyAbd El-Malak |
| -- | Randa Latif Aziz |
| -- | Rania Abd El-Baset Sanad |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Divisons | Department of Pharmaceutics and Industrial Pharmacy |
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) | |
| Cataloger | Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Not for loan | Home library | Current library | Date acquired | Full call number | Barcode | Date last seen | Koha item type |
|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | Not for loan | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 11.02.2024 | Cai01.08.10.Ph.D.2023.Re.P | 01010110087950000 | 17.12.2023 | Thesis |